Comparing continuous and intermittent vancomycin infusion for kidney health
A Randomized Clinical Trial of Continuous vs. Intermittent Infusion Vancomycin: Effects on Measured GFR and Kidney Injury Biomarkers
This study is looking at whether giving the antibiotic vancomycin continuously or in bursts is better for protecting your kidneys while you're in the hospital, and it's for patients who are already receiving this medication.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kentucky NIH-funded |
| Lab location | 1 site (Lexington, United States) |
| Project ID | NIH-10766824 on NIH RePORTER |
What this research studies
This research investigates how different methods of administering the antibiotic vancomycin—either continuously or intermittently—affect kidney function and injury in hospitalized patients. By conducting a randomized clinical trial, the study aims to determine if continuous infusion can reduce the risk of acute kidney injury associated with vancomycin use. Patients already receiving vancomycin will be monitored for changes in kidney function using advanced measures like glomerular filtration rate and kidney injury biomarkers. The goal is to provide clearer insights into the safest and most effective way to administer this critical antibiotic.
Who could benefit from this research
Good fit: Ideal candidates for this research are hospitalized patients who are currently prescribed vancomycin for treatment of infections.
Not a fit: Patients who are not receiving vancomycin or those with pre-existing severe kidney disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer vancomycin administration practices, reducing the risk of kidney injury in patients.
How similar studies have performed: Previous studies have shown promising results with continuous infusion methods in reducing kidney injury, suggesting potential for success in this trial.
Where this research is happening
Lexington, United States
- University of Kentucky — Lexington, United States (Active)
Researchers
- Principal investigator: Cook, Aaron M — University of Kentucky
- Study coordinator: Cook, Aaron M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.